FDA Matters founder Steven Grossman explains why he thinks it will take the Trump administration at least until the end of the year to name a new FDA commissioner and shepherd that appointment through the Senate confirmation process.
A Yale Journal on Regulation article from the Yale Law School Solomon Center for Health Law & Policy examines how the Supreme Court’s Loper Bright decision has and has not changed judicial actions involving federal health agencies.
FDA Matters founder Steven Grossman explains why he thinks it will take the Trump administration at least until the end of the year to name a new FDA commissioner and shepherd that appointment through the Senate confirmation process.
A Yale Journal on Regulation article from the Yale Law School Solomon Center for Health Law & Policy examines how the Supreme Court’s Loper Bright decision has and has not changed judicial actions involving federal health agencies.
The U.S. government urges the Supreme Court to reject an appeal by a Texas compounding pharmacy in a closely watched case over whether federal drug law preempts state-law claims challenging the sale of compounded drugs.
Senator Tom Cotton (R-AR) urges FDA and government cybersecurity officials to review Chinese-made medical devices cleared before updated cybersecurity requirements took effect.
